{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:42:08Z","timestamp":1792424528377,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403304"],"award-info":[{"award-number":["2023YFC3403304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403303"],"award-info":[{"award-number":["2023YFC3403303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471551"],"award-info":[{"award-number":["32471551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.canlet.2025.217752","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:13:39Z","timestamp":1745838819000},"page":"217752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Cancer mRNA vaccines: clinical application progress and challenges"],"prefix":"10.1016","volume":"625","author":[{"given":"Hang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217752_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.217752_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2025.217752_bib3","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.18632\/oncotarget.24309","article-title":"The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer","volume":"9","author":"Chakraborty","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.217752_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12943-024-02141-5","article-title":"Advances and applications of RNA vaccines in tumor treatment","volume":"23","author":"Yang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib6","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.abd3377","article-title":"COVID-19 and cancer","volume":"368","author":"Sharpless","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217752_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2021.01.003","article-title":"Advances in gene-based vaccine platforms to address the COVID-19 pandemic","volume":"170","author":"Pushparajah","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2025.217752_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","article-title":"Recent developments of RNA-based vaccines in cancer immunotherapy","volume":"21","author":"Faghfuri","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib10","first-page":"455","article-title":"The development of prophylactic and therapeutic EBV vaccines","volume":"391","author":"Smith","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41419-023-05786-0","article-title":"Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways","volume":"14","author":"Xie","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2025.217752_bib12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217752_bib13","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s00432-021-03735-y","article-title":"Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer","volume":"147","author":"Sun","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217752_bib15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2025.217752_bib16","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.7150\/thno.93745","article-title":"Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy","volume":"14","author":"Huang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2025.217752_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib18","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2025.217752_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2025.217752_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217752_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202004452","article-title":"Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo","volume":"32","author":"Zeng","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.canlet.2025.217752_bib23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2025.217752_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tcb.2018.11.002","article-title":"Tales of detailed poly(A) tails","volume":"29","author":"Nicholson","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2025.217752_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.21","article-title":"pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences","volume":"5","author":"Grier","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2025.217752_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.molcel.2016.04.007","article-title":"Regulation of poly(A) tail and translation during the somatic cell cycle","volume":"62","author":"Park","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","article-title":"Branched chemically modified poly(A) tails enhance the translation capacity of mRNA","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2025.217752_bib28","doi-asserted-by":"crossref","DOI":"10.1515\/med-2022-0625","article-title":"Silencing of circ_002136 sensitizes gastric cancer to paclitaxel by targeting the miR-16-5p\/HMGA1 axis","volume":"18","author":"Kuang","year":"2023","journal-title":"Open Med."},{"key":"10.1016\/j.canlet.2025.217752_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.682581","article-title":"An overview of RNA-based scaffolds for osteogenesis","volume":"8","author":"Damiati","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2025.217752_bib31","article-title":"Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects","volume":"16","author":"Wei","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41392-022-01175-9","article-title":"RNA modifications: importance in immune cell biology and related diseases","volume":"7","author":"Cui","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J. Contr. Release : official J. Control. Release. Society"},{"key":"10.1016\/j.canlet.2025.217752_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2025.217752_bib35","first-page":"30","article-title":"New generation vaccines for COVID-19 based on peptide, viral vector, artificial antigen presenting cell, DNA or mRNA","volume":"14","author":"Rezaei","year":"2022","journal-title":"Avicenna J. Med. Biotechnol. (AJMB)"},{"key":"10.1016\/j.canlet.2025.217752_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Contr. Release : official J. Control. Release. Society"},{"key":"10.1016\/j.canlet.2025.217752_bib37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.aad9868","article-title":"Translational control by 5'-untranslated regions of eukaryotic mRNAs","volume":"352","author":"Hinnebusch","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217752_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2015.973859","article-title":"mRNA transcript therapy","volume":"14","author":"Weissman","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.canlet.2025.217752_bib39","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1073\/pnas.94.6.2410","article-title":"Four highly stable eukaryotic mRNAs assemble 3' untranslated region RNA-protein complexes sharing cis and trans components","volume":"94","author":"Holcik","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.217752_bib40","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217752_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2010.02.036","article-title":"A role for codon order in translation dynamics","volume":"141","author":"Cannarozzi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib42","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/eji.200636617","article-title":"Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides","volume":"36","author":"Diebold","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11033-021-06749-4","article-title":"Codon usage bias","volume":"49","author":"Parvathy","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2025.217752_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2025.217752_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2025.217752_bib46","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1261\/rna.528007","article-title":"Improved native affinity purification of RNA","volume":"13","author":"Batey","year":"2007","journal-title":"Rna"},{"key":"10.1016\/j.canlet.2025.217752_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122279","article-title":"Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy","volume":"301","author":"Yan","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2025.217752_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1992","article-title":"Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics","volume":"16","author":"Jiao","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2025.217752_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.canlet.2025.217752_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2025.217752_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2012.04.008","article-title":"Virus-mediated gene delivery for human gene therapy","volume":"161","author":"Giacca","year":"2012","journal-title":"J. Contr. Release : official J. Control. Release. Society"},{"key":"10.1016\/j.canlet.2025.217752_bib53","first-page":"12711","article-title":"mRNA-based cancer vaccines: advancements and prospects","volume":"24","author":"Wu","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2025.217752_bib54","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.canlet.2025.217752_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2025.217752_bib56","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib57","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","article-title":"Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines","volume":"5","author":"Goswami","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.canlet.2025.217752_bib58","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.217752_bib59","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/gutjnl-2024-332784","article-title":"Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system","volume":"74","author":"Liu","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2025.217752_bib60","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.cell.2024.07.023","article-title":"Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles","volume":"187","author":"Brown","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2025.217752_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121303","article-title":"Dendrimers in vaccine delivery: recent progress and advances","volume":"280","author":"Chowdhury","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2025.217752_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.canlet.2025.217752_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.semcancer.2023.02.002","article-title":"Extracellular vesicles as next generation immunotherapeutics","volume":"90","author":"Greening","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2025.217752_bib66","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s13346-024-01710-x","article-title":"Exosome-based drug delivery systems for enhanced neurological therapeutics","volume":"15","author":"Vahab","year":"2025","journal-title":"Drug Deliv Transl Res."},{"key":"10.1016\/j.canlet.2025.217752_bib67","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/vaccines11081334","article-title":"RNA vaccines: yeast as a novel antigen vehicle","volume":"11","author":"Silva","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2025.217752_bib68","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2025.217752_bib69","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.canlet.2025.217752_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2967\/jnmt.121.262049","article-title":"Intramuscular injections for COVID-19 vaccinations","volume":"49","author":"Thomas","year":"2021","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.canlet.2025.217752_bib71","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/pharmaceutics12111042","article-title":"Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments","volume":"12","author":"Zhang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2025.217752_bib72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.omto.2021.08.009","article-title":"An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model","volume":"22","author":"Kitagawa","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2025.217752_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121707","article-title":"Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis","volume":"288","author":"Sung","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2025.217752_bib74","first-page":"3301","article-title":"[Microneedle-based percutaneous immunity: a review]","volume":"38","author":"Li","year":"2022","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.canlet.2025.217752_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113919","article-title":"Microneedle-mediated vaccination: innovation and translation","volume":"179","author":"Sheng","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2025.217752_bib76","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/acs.nanolett.0c05039","article-title":"In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy","volume":"21","author":"Yin","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2025.217752_bib77","article-title":"mRNA vaccines: the dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217752_bib79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.710647","article-title":"Influenza viruses: innate immunity and mRNA vaccines","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib81","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife's edge: balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jconrel.2024.10.035","article-title":"Recent advances in mRNA-based cancer vaccines encoding immunostimulants and their delivery strategies","volume":"376","author":"Eslami","year":"2024","journal-title":"J. Contr. Release : official J. Control. Release. Society"},{"key":"10.1016\/j.canlet.2025.217752_bib83","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/d41573-023-00118-5","article-title":"Personalized cancer vaccines pass first major clinical test","volume":"22","author":"Dolgin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217752_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2539","article-title":"A phase I study to evaluate the safety and tolerability of JCXH-211 (a self-replicating mRNA encoding IL-12) intratumoral injection in patients with malignant solid tumors: results from the phase Ia dose escalation","volume":"42","author":"Le","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib89","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB198","article-title":"Abstract LB198: a first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors","volume":"83","author":"Bechter","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib88","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-6552","article-title":"Abstract 6552: intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L\/IL-23\/IL-36\u03b3 in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors","volume":"84","author":"Abadier","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib133","article-title":"Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib134","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT004","article-title":"Abstract CT004: intratumoral (IT) MEDI1191 + durvalumab (D): update on the first-in-human study in advanced solid tumors","volume":"83","author":"Casta\u00f1\u00f3n","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib135","article-title":"549 an RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion","volume":"9","author":"Loquai","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib136","article-title":"421 A first-in-human (FIH) phase I\/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT","volume":"9","author":"Linch","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.938","article-title":"877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC","volume":"35","author":"Saba","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib138","article-title":"1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition","volume":"12","author":"Atmaca","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib139","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1016\/j.annonc.2024.08.729","article-title":"663P First-in-human, phase I\/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1\/Ido1 antigen-specific therapy, in advanced\/refractory solid tumors","volume":"35","author":"Khattak","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib140","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT141","article-title":"Abstract CT141: mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): clinical & translational analysis","volume":"84","author":"Bauman","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib142","doi-asserted-by":"crossref","unstructured":"Delord, J.-P. et al. Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol. 40, 2637-2637, doi:10.1200\/JCO.2022.40.16_suppl.2637.","DOI":"10.1200\/JCO.2022.40.16_suppl.2637"},{"key":"10.1016\/j.canlet.2025.217752_bib143","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.6082","article-title":"Safety and immunogenicity of TG4050: a personalized cancer vaccine in head and neck carcinoma","volume":"41","author":"Ottensmeier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib144","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-73","article-title":"Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes","volume":"81","author":"Awad","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib145","doi-asserted-by":"crossref","unstructured":"Zhan, X. et al. Phase I trial of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms. J. Clin. Oncol. 38, e15269-e15269, doi:10.1200\/JCO.2020.38.15_suppl.e15269.","DOI":"10.1200\/JCO.2020.38.15_suppl.e15269"},{"key":"10.1016\/j.canlet.2025.217752_bib97","doi-asserted-by":"crossref","unstructured":"Balachandran, V. P. et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. J. Clin. Oncol. 40, 2516-2516, doi:10.1200\/JCO.2022.40.16_suppl.2516.","DOI":"10.1200\/JCO.2022.40.16_suppl.2516"},{"key":"10.1016\/j.canlet.2025.217752_bib84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","article-title":"Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells","volume":"4","author":"Van Lint","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.217752_bib85","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2025.217752_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib87","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT032","volume":"80","author":"Jimeno","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib91","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.cgt.7700961","article-title":"Phase I\/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA","volume":"13","author":"Kyte","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib92","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/bloodadvances.2021005941","article-title":"Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant","volume":"6","author":"Chung","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2025.217752_bib93","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217752_bib96","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/2159-8290.CD-NB2023-0028","article-title":"mRNA vaccine slows melanoma recurrence","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217752_bib98","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217752_bib99","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","article-title":"Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides","volume":"625","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217752_bib100","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","article-title":"RNA vaccines for cancer: principles to practice","volume":"42","author":"Guasp","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib103","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib104","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102611118","article-title":"Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads","volume":"118","author":"Lussier","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2025.217752_bib106","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib107","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.macromol.2c00854","article-title":"Immunostimulatory polymers as adjuvants, immunotherapies, and delivery systems","volume":"55","author":"Weiss","year":"2022","journal-title":"Macromolecules"},{"key":"10.1016\/j.canlet.2025.217752_bib108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib109","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","article-title":"Humanized mouse models of clinical disease","volume":"12","author":"Walsh","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.canlet.2025.217752_bib110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri2017","article-title":"Humanized mice in translational biomedical research","volume":"7","author":"Shultz","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj3671","article-title":"Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy","volume":"8","author":"Bonaventura","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2025.217752_bib114","article-title":"Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217752_bib115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41568-020-0241-6","article-title":"Tumour heterogeneity and the evolutionary trade-offs of cancer","volume":"20","author":"Hausser","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib116","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217752_bib117","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s40478-019-0851-y","article-title":"Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas","volume":"7","author":"Al-Ali","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.canlet.2025.217752_bib118","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.217752_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003220","article-title":"Phase I\/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma","volume":"9","author":"Patel","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217752_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.b.35530","article-title":"Microfluidics based particle and droplet generation for gene and drug delivery approaches","volume":"113","author":"Onan","year":"2025","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.canlet.2025.217752_bib122","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2025.217752_bib123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.canlet.2025.217752_bib124","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","article-title":"Circular RNA in cancer","volume":"24","author":"Conn","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217752_bib125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217752_bib126","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s42256-024-00901-y","article-title":"Sliding-attention transformer neural architecture for predicting T cell receptor\u2013antigen\u2013human leucocyte antigen binding","volume":"6","author":"Feng","year":"2024","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.canlet.2025.217752_bib127","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2025.217752_bib128","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2025.217752_bib129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2025.217752_bib130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. ther., Methods clin. dev."},{"key":"10.1016\/j.canlet.2025.217752_bib131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41577-021-00554-7","article-title":"Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms","volume":"22","author":"Lynn","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217752_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104430","article-title":"The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients","volume":"88","author":"Alexander","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:37:04Z","timestamp":1762288624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525003180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":145,"alternative-id":["S0304383525003180"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217752","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer mRNA vaccines: clinical application progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217752"}}